Efficacité clinique du 2L®ALERG, un nouveau traitement de type immunomodulateur par voie sublinguale dans le rhume des foins une étude en double insu contre placebo
(2011) Revue Francaise d’Allergologie — Vol. 51, n° 4, p. 430-436 (2011)
Files
pdfdocument.pdf
Restricted Access - Adobe PDF
- 395.96 KB
Details
- Authors
- Abstract
- Objective of the study: The usual treatment of seasonal allergic rhinitis is based on allergen eviction (illusory for pollens), immunotherapy and anti-allergic drugs. Micro-immunotherapy is a new therapeutic approach that uses a family of immunological chemical mediators to re-educate the immune system. This study evaluates the clinical efficacy of 2L<sup>®</sup>ALERG, a new immunomodulatory drug for the symptoms of seasonal allergic rhinitis. Patients and methods: Forty-one patients (six to 41 years old) were included in a double-blind placebo-controlled study. 2L<sup>®</sup>ALERG is composed of sublingual capsules containing diluted and succussed cytokines and nucleic acids, targeting anti-inflammatory and anti-immunoglobulin-E responses. Results: The study has been focused onto the grass pollen season peak in the south of Belgium in 2004. No significant improvement of symptoms score (T5SS) has been observed in the active group (p=0.33). A significant decrease in rescue medication consumption has been evidenced (-48% ; p=0.002), as well as an improvement of a global symptom and medication score (p=0.017). The number of days free of any rescue medication was highly significantly decreased in the active group (-20% ; p<0.0001). No side effects were noted. Conclusion: 2L<sup>®</sup>ALERG is effective in the treatment of seasonal allergic rhinitis and is well tolerated. Larger scale studies are nevertheless needed to confirm these data. © 2011 Elsevier Masson SAS.
- Affiliations
Citations
Van der Brempt, X., Cumps, J., & Capieaux, E. (2011). Efficacité clinique du 2L®ALERG, un nouveau traitement de type immunomodulateur par voie sublinguale dans le rhume des foins une étude en double insu contre placebo. Revue Francaise d’Allergologie, 51(4), 430-436. https://doi.org/10.1016/j.reval.2011.03.008 (Original work published 2011)